drugset / Trial / NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel or Lisocabtagene Maraleucel * Emapalumab
Timeline
- Start
- 2024-09-18
- Primary completion
- 2027-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 10 mg | Oral |
| Subject | Emapalumab | Monoclonal antibody | 3 mg/kg | — |
| Background | Axicabtagene Ciloleucel | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Lisocabtagene Maraleucel | Cell therapy | — | Intravenous |